Nanogen Awarded Additional Patents for Diabetes, Alzheimer's Disease Biomarkers

Oct 30, 2006, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:  
 NGEN), developer of advanced diagnostic products, announced today that it
 has been issued four patents by the U.S. Patent and Trademark Office for
 inventions related to diabetes and Alzheimer's disease biomarkers. The
 current patents are the most recent in a series describing biomarkers
 associated with these diseases.
     (Logo: )
     U.S. Patent No. 7,125, 678, "Protein biopolymer markers predictive of
 type II diabetes," U.S. Patent No. 7, 097,989, "Complement C3 precursor
 biomarker predictive of type II diabetes," and U.S. Patent No. 7,094,549,
 "Fibronectin biopolymer marker indicative of insulin resistance," relate to
 the use of mass spectrometry and time-of-flight detection to identify
 biopolymers that characterize type II diabetes. These markers could
 potentially be used in applications of disease risk assessment and
 development of therapeutic avenues.
     In addition, U.S. Patent No. 7,101,680 "Method for detecting the
 presence of monomeric brain associated human glutamine synthetase," relates
 to a method for detecting a biochemical marker, human glutamine synthetase,
 by immunoassay as a potential diagnostic for Alzheimer's disease. In
 addition, a method for distinguishing between AD and non-AD dementia is
     For information about licensing opportunities, contact Nanogen.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose,
 and ultimately help treat disease. The company's products include real-time
 PCR reagents, the NanoChip(R) electronic microarray platform and a line of
 rapid diagnostic tests. Nanogen's ten years of pioneering research
 involving nanotechnology holds the promise of miniaturization and continues
 to be supported for its potential for diagnostic and biodefense
 applications. For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements,
 including whether patents owned or licensed by Nanogen will be developed
 into products, whether the patents owned by Nanogen offer any protection
 against competitors with competing technologies, whether products under
 development can be successfully developed and commercialized, whether
 results reported by our customers or partners can be identically
 replicated, and other risks and uncertainties discussed under the caption
 "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
 Form 10-Q most recently filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof. Nanogen
 disclaims any intent or obligation to update these forward-looking

SOURCE Nanogen, Inc.